Balyasny Asset Management’s Aspire Biopharma Warrant ASBPW Stock Holding History

Balyasny Asset Management’s Portfolio ASBPW Stock Details ASBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-200,000	Closed	-$8.36K	–	2893
2023 Q1	$8.36K	Hold	200,000	–	–	﹤0.01%	2504
2022 Q4	$16K	Hold	200,000	–	–	﹤0.01%	2509
2022 Q3	$29K	Hold	200,000	–	–	﹤0.01%	2536
2022 Q2	$24K	Buy	+200,000	New	+$43.5K	﹤0.01%	2457

Other funds holding ASBPW

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

SFM

Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return

Balyasny Asset Management's ASBPW Position: Q2 2023 in Review

Balyasny Asset Management sold out of Aspire Biopharma Warrant (ASBPW) in Q2 2023, closing a stake of 200,000 shares — an estimated $8.36K sold.

Balyasny Asset Management first reported a position in ASBPW in Q2 2022 and held it in 4 quarters. The position peaked at $29K in Q3 2022. 40 funds tracked by Wall St. Rank hold ASBPW as of Q2 2023.

Balyasny Asset Management reported no remaining Aspire Biopharma Warrant position as of Q2 2023 after selling out during the quarter.
Balyasny Asset Management sold 200,000 Aspire Biopharma Warrant shares in Q2 2023, an estimated $8.36K.
Balyasny Asset Management first reported a position in Aspire Biopharma Warrant in Q2 2022 and held it in 4 quarters.
Balyasny Asset Management's Aspire Biopharma Warrant position peaked at $29K in Q3 2022.
40 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q2 2023.

Based on Balyasny Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.